NasdaqGM - Nasdaq Real Time Price USD
Adicet Bio, Inc. (ACET)
As of 2:43 PM EDT. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
--
--
24,990.0000
9,730.0000
17,903.0000
Operating Expense
128,084.0000
132,576.0000
97,541.0000
71,163.0000
57,094.0000
Operating Income
-128,084.0000
-132,576.0000
-72,551.0000
-61,433.0000
-39,191.0000
Net Non Operating Interest Income Expense
10,612.0000
9,953.0000
3,680.0000
-85.0000
651.0000
Other Income Expense
-19,819.0000
-20,035.0000
-919.0000
-606.0000
-953.0000
Pretax Income
-137,291.0000
-142,658.0000
-69,790.0000
-62,124.0000
-39,493.0000
Tax Provision
--
--
--
-125.0000
-2,815.0000
Net Income Common Stockholders
-137,291.0000
-142,658.0000
-69,790.0000
-61,999.0000
-36,678.0000
Diluted NI Available to Com Stockholders
-137,291.0000
-142,658.0000
-69,790.0000
-61,999.0000
-36,678.0000
Basic EPS
-2.52
-3.31
-1.70
-2.00
-5.01
Diluted EPS
-2.52
-3.31
-1.70
-2.00
-5.01
Basic Average Shares
63,987.8570
43,042.4050
41,080.2860
30,952.1520
7,319.9770
Diluted Average Shares
63,987.8570
43,042.4050
41,080.2860
30,952.1520
7,319.9770
Total Operating Income as Reported
-147,546.0000
-152,038.0000
-72,551.0000
-61,433.0000
-39,191.0000
Total Expenses
128,084.0000
132,576.0000
97,541.0000
71,163.0000
57,094.0000
Net Income from Continuing & Discontinued Operation
-137,291.0000
-142,658.0000
-69,790.0000
-61,999.0000
-36,678.0000
Normalized Income
-117,829.0000
-123,196.0000
-69,790.0000
-61,999.0000
-36,678.0000
Interest Income
10,616.0000
9,978.0000
3,760.0000
91.0000
785.0000
Interest Expense
4.0000
25.0000
80.0000
176.0000
134.0000
Net Interest Income
10,612.0000
9,953.0000
3,680.0000
-85.0000
651.0000
EBIT
-137,287.0000
-142,633.0000
-69,710.0000
-61,948.0000
-39,359.0000
EBITDA
-130,700.0000
-136,535.0000
-67,135.0000
-60,410.0000
-38,133.0000
Reconciled Depreciation
6,587.0000
6,098.0000
2,575.0000
1,538.0000
1,226.0000
Net Income from Continuing Operation Net Minority Interest
-137,291.0000
-142,658.0000
-69,790.0000
-61,999.0000
-36,678.0000
Total Unusual Items Excluding Goodwill
-19,462.0000
-19,462.0000
--
--
--
Total Unusual Items
-19,462.0000
-19,462.0000
--
--
--
Normalized EBITDA
-111,238.0000
-117,073.0000
-67,135.0000
-60,410.0000
-38,133.0000
Tax Rate for Calcs
--
--
--
0.0000
0.0001
12/31/2020 - 1/26/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
CTMX CytomX Therapeutics, Inc.
1.1550
+3.12%
RLYB Rallybio Corporation
1.0900
0.00%
MRSN Mersana Therapeutics, Inc.
2.0850
-2.11%
DSGN Design Therapeutics, Inc.
5.61
+4.08%
PMVP PMV Pharmaceuticals, Inc.
1.5850
+6.38%
NKTX Nkarta, Inc.
4.2200
+6.30%
XLO Xilio Therapeutics, Inc.
0.8000
0.00%
ERAS Erasca, Inc.
2.8500
+1.42%
HOWL Werewolf Therapeutics, Inc.
2.0487
+1.93%
PASG Passage Bio, Inc.
0.5830
+0.34%